# Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia

> **NCT01960413** · PHASE2 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 46 (actual)

## Conditions studied

- Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)

## Interventions

- **DRUG:** Montelukast added to Hydroxyurea
- **DRUG:** Placebo added to Hydroxyurea

## Key facts

- **NCT ID:** NCT01960413
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-03-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01960413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01960413, "Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01960413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*